Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway

Acquired resistance to BRAF kinase inhibitors (BRAFi) is the primary cause for their limited clinical benefit. Although several mechanisms of acquired BRAFi resistance have been identified, the basis for acquired resistance remains unknown in over 40% of melanomas. We performed a large-scale short-h...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Proc Natl Acad Sci U S A
Main Authors: Gupta, Romi, Bugide, Suresh, Wang, Biao, Green, Michael R., Johnson, Douglas B., Wajapeyee, Narendra
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2019
Teme:
PNAS Plus
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6410847/
https://ncbi.nlm.nih.gov/pubmed/30782837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1821889116
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki